
COGNITION THERAPEUTICS INC
COGNITION THERAPEUTICS INC (CGTX)
WebsitePrice
Market cap
Next catalystSecond half of 2027, after the last participants have completed 18 months of treatmentZervimesine (CT1812) — START and prior Alzheimer’s studies · Phase 2 dataCompany source ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Representative pipeline applications
Clinical
Upcoming clinical milestones
PreINDP1P2FilingApproved
History / paused
PreINDP1P2P3FilingApproved